Overview

Effects of Interleukin (IL)- 4R-alpha Inhibition on Respiratory Microbiome and Immunologic Correlates in Severe Asthma

Status:
Not yet recruiting

Trial end date:
2023-10-01

Target enrollment:

Participant gender:

Summary

The overall goal of this study is to understand biological responses related to dupilumab treatment among severe asthma patients. Not all asthma is the same, and characteristics of asthma vary from person to person. The study will investigate whether the study drug can help to improve the health of participants lungs, boost immune response, as well as improve quality of life.

Phase:

Phase 4

Details

Lead Sponsor:

University of Michigan

Collaborator:

Regeneron Pharmaceuticals